DelveInsight, a leading market research and business consulting company, has released its latest report, “Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast – 2036.” The report offers a comprehensive analysis of Interstitial Cystitis, covering epidemiology trends, current treatment practices, emerging therapies, market dynamics, and forecasted market growth across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Key Takeaways from the Interstitial Cystitis Market Report
The Interstitial Cystitis market size in the 7MM is projected to grow steadily through 2036.
In 2025, the total diagnosed prevalent cases of Interstitial Cystitis in the 7MM were approximately 3.5 million.
The United States accounted for the largest Interstitial Cystitis market size among the 7MM in 2025, with more than USD 2 billion.
DelveInsight analysis indicates that the US represented more than 55% of total prevalent Interstitial Cystitis cases in the 7MM in 2025.
Within EU4 and the UK, Germany accounted for the highest market size at approximately USD 290 million in 2025.
In Japan, around 75% of Interstitial Cystitis cases were classified as mild, while 22% were moderate and nearly 3% severe in 2025.
Females represented approximately 60% of Interstitial Cystitis cases in the US in 2025, highlighting a clear female predominance.
The Interstitial Cystitis treatment landscape currently includes only two approved therapies, ELMIRON (Johnson & Johnson) and ZYMSO (Kyorin Pharmaceuticals), underscoring the major unmet need for safer and more effective therapies.
Leading companies developing Interstitial Cystitis therapies include Vaneltix Pharma/Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, and Aska Pharmaceutical.
Promising emerging therapies include ALENURA (lidocaine + heparin), ONO-1110, SI-722, Sunobinop (V117957), and AKP-021.
Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr
Key Factors Driving the Interstitial Cystitis Market
Increasing Diagnosis Rates and Disease Awareness:- Growing awareness regarding chronic bladder pain syndromes, along with improved diagnostic approaches such as cystoscopy, urodynamics, and biomarker research, is contributing to earlier and more accurate diagnosis of Interstitial Cystitis.
Rising Adoption of Multimodal Treatment Approaches:- The management of Interstitial Cystitis increasingly relies on individualized treatment strategies involving oral medications, intravesical therapies, pelvic floor therapy, neuromodulation, behavioral modifications, and supportive care approaches.
Growing Demand for Novel and Safer Therapies:- Current therapies are often associated with limited efficacy and safety concerns. For example, long-term retinal toxicity risks associated with pentosan polysulfate sodium are increasing the demand for safer alternatives with improved clinical outcomes.
Advancements in Emerging Pipeline Therapies:- The pipeline for Interstitial Cystitis is expanding with innovative candidates targeting pain relief, inflammation control, bladder lining repair, and neuromodulation pathways. These emerging therapies are expected to reshape future treatment paradigms.
Interstitial Cystitis Competitive Landscape
The Interstitial Cystitis pipeline includes several promising candidates in mid- and late-stage clinical development such as ALENURA (Vaneltix Pharma/Hyloris Pharma), ONO-1110 (Ono Pharmaceutical), SI-722 (Seikagaku Corporation), Sunobinop/V117957 (Imbrium Therapeutics), and AKP-021 (Aska Pharmaceutical).
These therapies target diverse mechanisms including glycosaminoglycan stimulation, anti-inflammatory pathways, nociceptin/orphanin-FQ peptide receptor agonism, endocannabinoid regulation, and mPGES-1 inhibition. The growing focus on mechanism-based therapies reflects the increasing demand for more effective and personalized treatment options for Interstitial Cystitis patients.
Discover more about therapies set to grab major Bipolar Depression market share @ Interstitial Cystitis Treatment Landscape
Recent Developments in the Interstitial Cystitis Market
In March 2025, Hyloris announced a positive interim review outcome for the ALENURA clinical trial, with the Independent Data Monitoring Committee recommending continuation of the study. Patient enrollment is expected to be completed by the end of 2025.
In December 2024, Vaneltix Pharma initiated the VNX001-110 clinical trial to evaluate the safety, efficacy, and dosing frequency of ALENURA for Interstitial Cystitis treatment.
ALENURA currently holds patent protection until 2038, providing an extended commercialization opportunity window.
Japan continues to expand awareness and reimbursement access for therapies such as ZYMSO following its launch after NHI price listing approval.
What is Interstitial Cystitis?
Interstitial Cystitis is a chronic pelvic condition characterized by bladder pain, pressure, urinary urgency, frequency, and persistent inflammation without evidence of infection or other identifiable causes. Patients often experience severe discomfort, frequent urination, nocturia, and reduced quality of life. Diagnosis remains challenging because symptoms frequently overlap with other urinary and pelvic disorders, often resulting in delayed diagnosis.
Interstitial Cystitis Epidemiology Segmentation
The Interstitial Cystitis epidemiology section provides historical and forecasted epidemiological insights across the 7MM from 2022–2036, segmented into:
Total Prevalent Cases of Interstitial Cystitis
Total Diagnosed Prevalent Cases of Interstitial Cystitis
Age-specific Diagnosed Prevalent Cases of Interstitial Cystitis
Gender-specific Diagnosed Prevalent Cases of Interstitial Cystitis
Severity-specific Diagnosed Prevalent Cases of Interstitial Cystitis
Type-specific Diagnosed Prevalent Cases of Interstitial Cystitis
Total Treated Cases of Interstitial Cystitis
Scope of the Interstitial Cystitis Market Report
Therapeutic Assessment: Current marketed and emerging Interstitial Cystitis therapies
Interstitial Cystitis Market Dynamics: Market drivers, barriers, and future opportunities
Key Companies: Johnson & Johnson, Kyorin Pharmaceuticals, Vaneltix Pharma, Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, Aska Pharmaceutical, and others
Key Therapies: ELMIRON, ZYMSO, ALENURA, ONO-1110, SI-722, Sunobinop (V117957), AKP-021, and others
Competitive Intelligence Analysis: SWOT analysis and market entry strategies
Unmet Needs, KOL perspectives, Analyst views, and Market Access & Reimbursement analysis
To know more about Bipolar Depression companies working in the treatment market, visit @ Interstitial Cystitis Market Clinical Trials and Therapeutic Assessment
Table of Contents
Key Insights
Report Introduction
Interstitial Cystitis Market Overview
Methodology of Epidemiology and Market
Executive Summary
Key Events
Disease Background and Overview
Epidemiology and Patient Population
Patient Journey
Marketed Therapies
Emerging Therapies
Interstitial Cystitis – 7MM Market Analysis
Key Opinion Leaders’ Views
SWOT Analysis
Unmet Needs
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading business consultant and market research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve business performance. DelveInsight offers healthcare market research reports through its subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: https://www.delveinsight.com/consulting/due-diligence-servicesCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
